preconfer
workshop
nut
bolt
antibodi
develop
acceler
antibodi
drug
clinic
cochair
jame
larrick
panorama
research
institut
veloc
pharmaceut
develop
llc
mark
alfenito
engen
bio
inc
silver
anniversari
antibodi
engin
therapeut
meet
kick
dynam
audienceparticipatori
workshop
antibodi
drug
develop
chair
veteran
jim
larrick
panorama
research
institut
veloc
pharmaceut
develop
llc
mark
alfenito
engen
bio
inc
follow
dr
larrick
introductori
remark
regard
investor
perspect
therapeut
antibodi
drug
max
vasquez
adimab
describ
stateoftheart
bioinformat
silico
method
facilit
preclin
antibodi
develop
akbar
nayeem
molecular
discoveri
technolog
expand
topic
describ
comput
method
optim
structur
clinic
candid
antibodi
next
nicola
beaucamp
roch
innov
center
penzberg
describ
roch
integr
approach
chines
hamster
ovari
cho
cell
line
select
upstream
process
downstream
process
analyt
deliv
highqual
bispecif
antibodi
follow
break
workshop
conclud
case
studi
first
dorina
saro
johnson
johnson
develop
analyt
biophys
tool
select
bispecif
monoclon
antibodi
mab
candid
focu
product
develop
second
thisau
migon
igenica
biotherapeut
cover
proteomicbas
discoveri
novel
hematolog
cancer
target
inden
studi
sitespecif
antibodydrug
conjug
adc
anticip
excit
inform
workshop
preconfer
workshop
b
advanc
precis
target
chair
paul
whi
parren
genmab
precis
target
biopharmaceut
remain
major
challeng
almost
therapeut
area
workshop
bring
togeth
number
expert
present
recent
key
knowledgebas
advanc
optim
target
bind
increas
specif
activ
extens
audienc
particip
discuss
encourag
juergen
schanzer
roch
innov
center
penzberg
discuss
xgfr
novel
glycoengin
bispecif
antibodi
scaffold
target
egfr
combin
potent
signal
inhibit
antibodydepend
cellmedi
cytotox
adcc
demonstr
improv
target
properti
compar
tetraval
bispecif
format
christoph
thano
halozym
therapeut
sanjay
khare
immungen
inc
discuss
advanc
adc
target
improv
therapeut
index
dr
thano
engin
egfr
antibodi
increas
tumor
specif
lead
activ
krasbrafmut
tumor
vivo
dr
khare
demonstr
select
target
interferon
ifn
payload
reduc
system
toxic
break
david
corti
humab
biom
sa
turn
attent
infecti
diseas
escap
antibodi
target
remain
critic
topic
dr
corti
show
studi
number
antibodi
deriv
human
infect
employ
variou
antivir
mechan
allow
extraordinari
breadth
activ
rang
viru
subtyp
subfamili
rudolf
kerschbaum
baxter
innov
gmbh
discuss
novel
data
wellknown
pleiotrop
proinflammatori
cytokin
macrophag
migrat
inhibitori
factor
mif
use
phagedisplay
dr
kerschbaum
isol
antibodi
target
oxid
mif
oxmif
previous
unrecogn
diseaserel
variant
cytokin
interest
activ
cancerassoci
inflamm
vivo
tumor
growth
inhibit
final
yuki
iwayanagi
chugai
pharmaceut
co
ltd
complet
session
discuss
novel
approach
enhanc
clearanc
solubl
antigen
make
use
engin
antibodi
combin
phdepend
bind
activ
enhanc
select
igg
fc
receptor
overal
session
highlight
number
novel
insight
import
advanc
select
engin
antibodi
better
precis
bear
great
promis
develop
improv
immunotherapi
keynot
present
chair
jame
mark
univers
california
san
francisco
san
francisco
gener
hospit
meet
open
keynot
present
five
luminari
field
molecular
therapeut
develop
dougla
lauffenburg
massachusett
institut
technolog
discuss
system
analysi
cell
commun
network
dynam
therapeut
biolog
design
critic
contemporari
issu
molecular
therapeut
includ
biolog
efficaci
although
target
antibodi
protein
drug
identifi
specif
address
understand
effect
correspond
perturb
within
complex
tissu
pathophysiolog
context
requir
multivari
analysi
key
compon
myriad
cellular
molecular
actor
potenti
involv
execut
regul
phenotyp
behavior
integr
manner
dr
lauffenburg
inform
meet
particip
group
pursu
develop
vivo
system
biolog
approach
meet
challeng
ira
pastan
nation
cancer
institut
discuss
extens
experi
develop
recombin
immunotoxin
rit
compos
cancer
celltarget
fv
fab
fuse
portion
pseudomona
exotoxin
rit
target
either
leukemia
mesothelin
mesothelioma
produc
complet
dramat
remiss
patient
efficaci
limit
immunogen
capillari
leak
syndrom
cl
overcom
defici
dr
pastan
group
identifi
remov
b
tcell
epitop
sequenc
respons
cl
produc
new
immunotoxin
high
efficaci
low
immunogen
low
side
effect
recent
result
present
jame
well
univers
california
san
francisco
give
view
engin
antibodi
challeng
target
antibodi
phage
display
technolog
proven
use
select
high
qualiti
reliabl
renew
antibodi
mani
technolog
challeng
remain
howev
select
antibodi
activ
function
bind
specif
ptm
develop
high
throughput
technolog
dr
well
present
recent
work
select
conform
select
antibodi
activ
inhibitor
new
scaffold
antipeptid
antibodi
ptm
new
autom
platform
largescal
antibodi
phage
select
ian
tomlinson
glaxosmithklin
discuss
past
present
futur
antibodi
repertoir
twenti
year
pass
sinc
first
highaffin
antibodi
select
naiv
librari
without
use
anim
form
immun
today
mani
larg
librari
mani
differ
display
technolog
use
identifi
antibodi
antibodi
made
way
made
market
dr
tomlinson
present
view
event
last
two
decad
address
question
barrier
key
advanc
state
art
today
commemor
anniversari
confer
anthoni
ree
ree
consult
ab
emeritu
professor
univers
bath
provid
histor
perspect
antibodi
molecul
remark
journey
scientist
taken
tri
understand
function
prof
ree
recount
journey
includ
controversi
excit
beyond
belief
disappoint
truth
told
today
much
accid
result
logic
itinerari
track
immunocytokin
engin
cochair
jame
huston
antibodi
societi
huston
bioconsult
llc
stephen
gilli
proven
biopharmaceut
potenti
merit
cytokin
therapi
interleukin
il
administr
treat
cancer
long
recogn
block
routin
use
advers
side
effect
gener
toler
patient
dosag
necessari
therapeut
effect
barrier
elimin
observ
stephen
gilli
cowork
antibodytarget
stimul
cytotox
tcell
kill
tumor
cell
dose
far
threshold
toxic
genet
fuse
ctermini
h
chain
target
antibodi
sinc
antibodycytokin
fusion
protein
local
tumor
virtu
associ
antibodi
tumor
target
fusion
partner
concentr
exactli
need
local
effect
dose
far
system
therapeut
window
requir
alon
discoveri
made
antibodi
engin
emerg
new
gener
method
molecul
provid
antibodytarget
deliveri
human
therapeut
fusion
protein
four
pioneer
use
divers
approach
ie
varieti
fusion
protein
altern
cytokin
distinct
target
discuss
work
along
two
recent
convert
develop
immunocytokin
ic
therapeut
session
mark
pivot
junctur
singular
immunotherapeut
includ
present
latest
advanc
ic
engin
recent
clinic
result
stephen
gilli
proven
biopharmaceut
open
session
orient
audienc
background
ic
overal
field
discuss
progress
design
engin
entir
new
format
ic
intend
new
gener
ic
integr
cytokin
immunomodulatori
effect
antibodi
effector
function
achiev
signific
improv
ic
capabl
also
discuss
progress
clinic
studi
dario
neri
eth
describ
vigor
activ
engin
advanc
ic
util
treatment
differ
diseas
three
alreadi
advanc
phase
clinic
trial
recent
preclin
advanc
involv
trifunct
diabodi
immunotherapeut
combin
ic
sitespecif
conjug
maytansinoid
microtubular
inhibitor
display
except
potent
antitumor
activ
thu
open
prospect
new
class
tripartit
target
anticanc
agent
sheri
l
morrison
univers
california
lo
angel
contribut
mani
first
engin
antibodi
therapeut
includ
chimer
antibodi
human
c
domain
murin
v
domain
exemplifi
rituximab
scfv
fusion
ctermini
h
chain
igg
current
favor
design
tetraval
bispecif
antibodi
contribut
ic
field
earli
year
develop
interest
target
ifn
discuss
group
research
emphas
interest
antitumor
antibodyifn
fusion
protein
cancer
therapi
paul
sondel
univers
wisconsin
maintain
major
interest
ic
therapi
begin
studi
chimer
ab
fusion
protein
phd
scientist
particularli
wellqualifi
bridg
gap
preclin
studi
clinic
investig
patient
describ
insight
patient
sometim
distinct
mous
modelderiv
conclus
combin
ic
interest
dedic
develop
cure
childhood
neuroblastoma
continu
pursu
goal
import
clinic
trial
k
dane
wittrup
massachusett
institut
technolog
invent
antibodyyeast
display
librari
leverag
technolog
propel
research
divers
area
cancer
biolog
antibodi
engin
work
aspect
cellular
immunolog
much
past
decad
recent
becam
interest
definit
boundari
condit
design
object
ic
engin
discuss
session
ekkehard
moessner
roch
innov
center
head
protein
engin
roch
pharmaceut
research
earli
develop
discuss
progress
develop
novel
class
ic
includ
optim
tri
separ
cytokin
contribut
adcc
make
antibodi
fusion
without
fc
region
stimul
conclus
session
offer
mani
exampl
scientif
creativ
ongo
process
ic
field
conceptu
progress
understand
ic
mechan
action
provid
basi
advanc
molecular
design
improv
protocol
ic
administr
ultim
reinforc
addit
ic
therapi
routin
clinic
use
oncolog
area
medicin
track
highhang
fruit
target
difficult
antigen
chair
andrea
differ
select
method
phage
display
ribosom
display
yeast
display
becom
rather
matur
year
great
major
target
individu
protein
express
purifi
thu
handl
well
understood
rather
similar
manner
session
chair
andrea
challeng
target
explor
probabl
emphas
speaker
import
part
success
abil
produc
target
first
place
first
part
session
devot
integr
membran
protein
particularli
signific
extracellular
domain
problem
simpli
solv
express
extracellular
piec
two
key
exampl
difficult
protein
gproteincoupl
receptor
ion
channel
goe
without
say
two
protein
class
huge
potenti
diseaserelev
target
marku
enzelberg
morphosi
talk
challeng
select
antibodi
bind
gpcr
use
stabil
gpcr
obtain
either
direct
evolut
alanin
scan
help
endeavor
furthermor
advanc
screen
method
play
decis
role
differ
approach
present
michael
gallo
innov
target
solut
gener
antibodi
receptor
glucagon
receptor
two
class
b
gpcr
antibodi
engin
contain
piec
natur
ligand
librari
gener
principl
ion
channel
group
challeng
membran
protein
stefan
zahn
novo
nordisk
present
approach
target
tcell
specif
ion
channel
crac
approach
necessari
achiev
talk
andrea
univers
zurich
differ
challeng
address
possibl
direct
target
agent
cytoplasm
high
effici
would
obvious
allow
attack
whole
new
set
target
previous
thought
undrugg
challeng
engin
cellspecif
uptak
mechan
much
effici
much
less
celltox
tradit
use
cellpenetr
peptid
hypercharg
protein
yet
anoth
challeng
gener
specif
antibodi
nonprotein
eg
glycan
interest
sinc
glycan
massiv
overexpress
tumor
might
therefor
constitut
gener
use
target
lindi
durrant
univers
nottingham
present
new
result
antibodi
target
specif
glycan
much
technolog
develop
might
shortcut
possibl
design
antibodi
bind
site
de
novo
structur
defin
surfac
sarel
fleishman
weizmann
institut
give
updat
possibl
use
rosetta
softwar
packag
experiment
valid
novel
binder
morn
track
high
qualiti
research
antibodi
proteom
chair
andrew
bradburi
lo
alamo
nation
laboratori
current
lack
standard
renew
lowcost
protein
affin
reagent
imped
progress
biomed
research
session
updat
particip
number
initi
intend
produc
distribut
reagent
extend
chairman
introductori
remark
andrew
bradburi
provid
insight
problem
exist
research
antibodi
relat
function
character
reproduc
propos
possibl
solut
follow
andrea
univers
inimit
manner
open
session
examin
whether
creat
repertoir
bind
agent
protein
practic
compar
altern
approach
technolog
develop
implement
creat
affin
reagent
rapidli
high
throughput
demand
requir
intend
experi
david
l
rimm
yale
univers
school
medicin
relat
group
experi
use
antibodi
research
clinic
set
show
error
assess
valid
produc
flaw
data
also
provid
guidelin
antibodi
valid
use
avoid
problem
anthoni
kossiakoff
univers
chicago
updat
particip
activ
recombin
antibodi
network
ran
intern
consortium
expert
center
univers
chicago
univers
toronto
univers
california
san
francisco
center
unifi
common
set
goal
technolog
oper
procedur
robot
technolog
platform
capabl
gener
highqual
recombin
antibodi
high
throughput
manner
ran
current
undertak
larg
proteomicsbas
project
rapidli
produc
valid
distribut
high
impact
antibodi
commun
andrew
bradburi
lo
alamo
nation
laboratori
describ
gener
renew
recombin
polyclon
antibodi
use
combin
phage
yeast
display
analysi
polyclon
use
nextgener
sequenc
roberto
polakiewicz
cell
signal
technolog
inc
discuss
current
problem
inadequ
valid
market
research
antibodi
potenti
problem
qualiti
larg
quantiti
antibodi
would
need
cover
whole
proteom
present
new
strategi
effect
discoveri
valid
high
qualiti
mab
progress
report
nation
institut
health
protein
captur
reagent
initi
given
seth
blackshaw
john
hopkin
univers
school
medicin
goal
initi
gener
distribut
standard
renew
lowcost
protein
affin
reagent
scientif
commun
dr
blackshaw
updat
particip
initi
progress
toward
gener
monospecif
mab
target
broad
rang
human
transcript
factor
morn
track
choos
target
bispecif
antibodi
difficult
chair
ian
tomlinson
glaxosmithklin
concept
hardwir
bind
specif
singl
antibodi
molecul
around
hundr
bispecif
preclin
clinic
develop
despit
avail
sever
valid
platform
make
bispecif
obviou
applic
combin
target
cancer
immunemedi
disord
one
real
challeng
remain
choos
precis
pair
target
go
format
haijun
sun
fstar
biotechnolog
open
session
present
fcab
fc
fragment
mablik
antigen
bind
capabl
fcab
serv
modular
platform
test
bispecif
target
combin
ration
design
empir
approach
also
develop
drug
replac
fc
mab
creat
bispecif
molecul
simon
chell
glaxosmithklin
discuss
effect
target
identif
stress
import
manufactur
new
antibodi
architectur
bispecif
antibodi
martin
steegmaier
roch
innov
center
penzberg
describ
care
target
select
develop
crossmab
technolog
creation
bispecif
heterodimer
antibodi
led
discoveri
molecul
effici
transfer
blood
brain
preclin
model
brain
shuttl
exploit
receptormedi
transcytosi
dual
target
shown
increas
target
engag
investig
antibodi
brain
compar
parent
antibodi
janin
schuurman
genmab
draw
experi
duobodi
platform
provid
gener
strategi
consider
bispecif
antibodi
discoveri
import
use
final
format
bispecif
discoveri
approach
illustr
surpris
result
found
select
lead
cmetxegfr
bispecif
antibodi
michael
stumpp
molecular
partner
updat
particip
latest
result
multispecif
darpin
includ
inhibitor
solubl
target
receptor
local
action
darpin
nonantibodi
small
bind
protein
proven
use
understand
biolog
target
combin
conclud
session
jiji
gu
abbvi
biopharmaceut
discuss
select
bispecif
target
pair
select
right
molecul
desir
pharmacolog
develop
properti
take
safeti
efficaci
molecul
consider
afternoon
track
antibodybas
therapeut
diabes
chair
jame
larrick
panorama
research
institut
veloc
pharmaceut
develop
novel
therapi
address
global
pandem
diabes
diabet
obes
urgent
need
session
chair
jame
larrick
panorama
research
institut
veloc
pharmaceut
develop
kick
session
provid
perspect
problem
potenti
role
antibodybas
therapeut
next
gerd
wallukat
max
center
molecular
medicin
describ
work
autoantibodi
aab
gpcr
found
sera
patient
cardiovascular
diseas
aab
direct
epitop
local
first
second
extracellular
loop
membranespan
hormon
receptor
act
like
correspond
agonist
aab
direct
epitop
induc
agonistlik
effect
crosslink
stabil
activ
receptor
conform
contrast
classic
agonist
function
aab
prevent
receptor
desensit
normal
seen
receptor
stimul
longer
time
agonist
aab
act
like
correspond
receptor
agonist
prevent
receptor
desensit
aab
may
play
role
pathogenesi
sever
cardiometabol
diseas
superior
glucos
regul
energi
balanc
desir
treatment
diabes
variou
glucagonlik
peptid
glp
therapi
eg
liraglutid
exenatid
dulaglutid
exhibit
efficaci
glycem
control
limit
weight
reduct
patient
bo
yu
larix
bioscienc
llc
describ
effort
improv
fusion
util
antibodi
membran
switch
am
technolog
employ
switchabl
cellsurfac
display
fusion
protein
sachdev
sidhu
univers
toronto
develop
comprehens
set
synthet
antibodi
act
antagonist
agonist
fgfrklotho
signal
pathway
result
show
systemat
target
signal
pathway
enabl
ration
develop
biotherapeut
antibodi
display
differ
effect
modul
signal
pathway
relat
diabes
describ
break
maria
grove
medimmun
describ
approach
employ
medimmun
gener
potent
antibodi
therapeut
select
target
implic
diabes
lead
isol
affin
matur
strategi
preclin
data
antibodi
therapeut
discuss
next
mingyu
zhou
amgen
describ
develop
novel
lcat
protein
modul
hdl
metabol
revers
cholesterol
transport
rct
modifi
lcat
protein
fc
fusion
mlcatfc
exhibit
enhanc
enzym
activ
improv
manufactur
desir
pharmacokinet
pharmacodynam
properti
preclin
model
includ
cynomolgu
monkey
mlcatfc
administr
rabbit
gener
larg
hdl
particl
promot
revers
cholesterol
transport
rct
attenu
progress
atherosclerosi
panel
novel
agonist
human
antilcat
antibodi
suitabl
therapeut
develop
also
discuss
enorm
interest
blockbust
potenti
proprotein
convertas
subtilisinkexin
type
antibodi
final
present
jesper
gromada
regeneron
pharmaceut
focu
antibodi
therapi
regul
plasma
ldlc
angiopoietinlik
protein
increas
lipoprotein
lipas
activ
lower
circul
triglycerid
level
anticip
excit
afternoon
firstrat
scienc
import
field
afternoon
track
preclin
clinic
case
studi
emerg
target
new
approach
chair
kerri
chester
univers
colleg
london
open
remark
chair
kerri
chester
univers
colleg
london
introduc
seri
studi
focus
emerg
target
approach
potenti
expand
scope
current
immunotherapeut
diagnost
imag
agent
mesothelin
msln
becom
increasingli
attract
target
deliveri
potent
toxin
highli
express
rang
epitheli
cancer
limit
express
healthi
tissu
predict
low
nonspecif
toxic
klau
bosslet
roch
diagnost
gmbh
begin
give
updat
latest
work
recombin
antibodytoxin
fusion
protein
target
msln
deimmun
fragment
pseudomona
exotoxin
effect
quiescent
prolifer
tumor
cell
shown
potenti
clinic
develop
tripleneg
breast
gastric
cancer
immunotoxin
may
successor
classic
adc
develop
therapeut
antibodi
capabl
target
intracellular
protein
address
david
scheinberg
memori
sloan
ketter
cancer
center
work
constitut
paradigm
shift
pharmaceut
anticanc
antibodi
despit
abund
intracellular
tumor
target
tradit
direct
cellsurfac
extracellular
molecul
approach
exploit
fact
degrad
small
peptid
intracellular
protein
present
cell
surfac
pocket
major
histocompat
complex
mhc
class
molecul
present
focu
wilm
tumor
protein
intracellular
oncogen
transcript
factor
overexpress
wide
rang
cancer
limit
express
normal
adult
tissu
scheinberg
group
develop
antibodi
rmfpnapyl
rmf
wilm
hlaa
epitop
antibodi
gener
multipl
format
includ
glycoengin
human
enhanc
adcc
function
eskm
bispecif
form
result
preclin
evalu
murin
model
present
mark
cobbold
univers
birmingham
present
intrigu
approach
select
har
power
adapt
immun
use
immunogen
viral
epitop
coval
coupl
clinic
relev
antibodi
novel
therapeut
entiti
term
antibodypeptid
epitop
conjug
apec
design
releas
viral
antigen
proteolyt
cleavag
close
proxim
surfac
tumor
technolog
render
tumor
suscept
immun
attack
mimick
viral
infect
engag
potent
tcell
respons
engin
control
cell
engag
target
cell
vitro
vivo
work
use
demonstr
proofofconcept
chimer
antigen
receptor
car
fusion
protein
link
extracellular
antigen
bind
domain
usual
singl
chain
fv
scfv
intracellular
tcell
signal
domain
clinic
studi
patient
peripher
blood
tcell
engin
express
car
transduct
integr
vector
result
gener
antigen
specif
car
tcell
target
kill
cancer
cell
car
tcell
highli
potent
cellular
therapeut
despit
complex
treatment
emerg
realist
therapeut
option
clinic
refresh
break
martin
pule
univers
colleg
london
present
work
clinic
develop
car
discuss
challeng
find
tumor
target
accept
ontarget
offtumor
toxic
new
approach
direct
car
multipl
myeloma
use
highaffin
natur
ligand
rather
scfv
present
addit
concept
use
combinatori
approach
introduc
explor
abil
engin
cell
sampl
trigger
respons
pattern
antigen
express
target
cell
type
tyrosinekinaselik
oncoembryon
surfac
antigen
express
earli
develop
emerg
role
cancer
biolog
express
varieti
human
cancer
includ
solid
tumor
colon
lung
pancrea
chronic
lymphocyt
leukemia
cll
common
blood
malign
adult
express
enhanc
growth
surviv
migrat
cancer
initi
cell
vitro
vivo
thoma
j
kipp
moor
ucsd
cancer
center
show
latest
result
evalu
firstinclass
anticanc
stem
cell
antibodi
target
kipp
group
gener
human
anti
mab
clinic
use
mab
drug
recent
enter
phase
trial
evalu
whether
safe
welltoler
cancer
stem
celltarget
agent
patient
cll
michel
eisenblaett
king
colleg
london
conclud
session
discuss
multimod
molecular
imag
immun
cell
activ
antibodi
target
exosomeassoci
calcium
bind
protein
key
marker
activ
monocyt
result
vivo
fluoresc
radionuclid
imag
express
indic
util
new
target
diagnost
imag
immunosuppress
inflamm
work
ground
break
although
earli
detect
local
monitor
inflamm
crucial
tailor
individu
therapi
reliabl
biomark
detect
local
inflammatori
activ
predict
diseas
outcom
yet
avail
morn
track
antibodi
effector
function
cochair
denni
r
burton
scripp
research
institut
paul
whi
parren
genmab
wednesday
chair
denni
r
burton
paul
whi
parren
readi
kickoff
excit
session
antibodi
effector
function
fill
plenti
coffe
join
us
first
part
session
focus
interact
antibodi
igg
fc
receptor
mark
cragg
southampton
univers
show
data
novel
class
antagonist
antibodi
tumor
therapi
overcom
previous
experienc
drawback
inhibitori
signal
intern
bear
promis
combin
therapi
contemporari
therapeut
mab
mark
hogarth
burnett
institut
discuss
recent
data
identifi
critic
function
polymorph
human
macaqu
import
implic
research
well
nonclin
safeti
studi
human
mab
nonhuman
primat
david
szymkowski
xencor
present
case
studi
antibodi
fc
domain
exhibit
enhanc
bind
make
use
specif
function
antibodi
deriv
inhibit
b
cell
function
without
induc
deplet
wherea
antiig
antibodi
among
other
exploit
role
antigen
clearanc
mechan
action
follow
break
rob
de
jong
genmab
discuss
hexabodi
technolog
novel
platform
enhanc
effector
function
antibodi
bind
cognat
antigen
cell
surfac
develop
platform
built
novel
insight
provid
observ
fcmediat
hexamer
cell
surfac
requir
optim
complement
activ
sophia
karagianni
king
colleg
london
school
medicin
discuss
ige
excit
novel
class
antibodi
immunotherapi
cancer
unexpect
superior
activ
compar
match
igg
counterpart
richard
blumberg
brigham
women
hospit
conclud
session
present
recent
work
critic
previous
unappreci
role
interact
neonat
fc
receptor
fcrn
antibodi
modul
innat
adapt
immun
respons
summari
look
forward
eyeopen
session
number
best
studi
favorit
protein
shown
convey
novel
function
activ
therapeut
promis
thank
antibodi
alway
remain
learn
morn
track
new
target
applic
immun
checkpoint
inhibitor
chair
gregori
p
adam
fox
chase
cancer
center
antibodi
target
inhibitori
activ
receptor
immun
effector
cell
rapidli
emerg
power
agent
treatment
cancer
diseas
approv
ipilimumab
recent
pembrolizumab
treatment
melanoma
repres
first
like
larg
panel
clinicallyapprov
antibodi
capabl
modul
immun
respons
treat
varieti
diseas
block
inhibitori
receptor
promot
immun
respons
cancer
block
activ
receptor
diminish
autoimmun
respons
repres
obviou
applic
potenti
indic
like
includ
prevent
reject
organ
transplant
stimul
immun
system
fight
infecti
diseas
session
focu
recent
effort
develop
new
agent
relat
applic
session
open
sumit
k
subudhi
md
anderson
cancer
center
describ
recent
success
antibodi
improv
target
varieti
immun
checkpoint
includ
ico
shown
promis
preclin
studi
discuss
identif
promis
target
design
agent
potenti
therapeut
properti
stephen
willingham
stanford
univers
school
medicin
discuss
role
play
protect
cancer
cell
phagocytosi
innat
immun
system
describ
human
monoclon
antibodi
develop
group
block
interact
ligand
phagocyt
cell
dr
willingham
share
result
vivo
preclin
studi
demonstr
abil
inhibit
tumor
growth
metastasi
hematolog
malign
solid
tumor
novel
approach
inhibit
suppress
activ
treg
use
neutral
antibodi
direct
garp
glycoprotein
repetit
predomin
present
michael
saunder
argenx
antibodi
target
critic
epitop
garp
express
surfac
treg
block
abil
bind
play
key
role
tregmedi
immunosuppress
dr
saunder
share
evid
abil
one
antigarp
antibodi
inhibit
immun
suppress
mediat
treg
graftversushost
diseas
model
induc
transplant
human
pbmc
autolog
treg
immunocompromis
mice
suggest
potenti
role
antigarp
antibodi
treatment
cancer
chronic
infect
holbrook
kohrt
stanford
univers
discuss
role
play
activ
nk
cellmedi
adcc
cancer
present
result
studi
show
addit
agonist
antibodi
enhanc
antitumor
activ
rituximab
trastuzumab
cetuximab
vitro
vivo
work
led
earli
phase
clinic
trial
current
underway
inhibit
cell
costimul
emerg
attract
altern
use
highli
toxic
immunosuppress
drug
prevent
organ
transplant
reject
howev
clinic
trial
belatacept
novel
fusion
receptor
biolog
bind
high
affin
inhibit
costimul
signal
cell
achiev
success
seen
preclin
studi
flavio
vincenti
univers
california
san
francisco
describ
new
approach
use
combin
belatacept
inhibit
pathway
possibl
infus
regulatori
cell
increas
belatacept
efficaci
prevent
renal
transplant
reject
therapi
interfer
promis
clinic
mani
cancer
patient
fail
respond
therapi
ana
carrizosa
anderson
harvard
medic
school
describ
work
studi
tim
famili
molecul
regul
cell
respons
develop
evalu
agent
block
signal
novel
checkpoint
target
afternoon
track
engin
antibodi
develop
express
solubl
polyreact
chair
k
dane
wittrup
massachusett
institut
technolog
advanc
develop
therapeut
antibodi
lead
must
appropri
biophys
properti
well
suitabl
bind
affin
target
specif
function
activ
session
speaker
provid
practic
advic
design
select
antibodi
minim
downstream
problem
yan
wu
genentech
open
session
discuss
antibodi
lead
select
yingda
xu
adimab
describ
high
throughput
assay
target
detect
antibodi
self
crossinteract
predict
fate
antibodi
express
purif
storag
serum
clearanc
bojana
popov
medimmun
illustr
silico
spatial
aggreg
propens
tool
use
conjunct
antibodi
engin
improv
stabil
pharmacokinet
profil
antinerv
growth
factor
mab
without
compromis
potenc
affin
silk
hansen
roch
innov
center
penzberg
describ
product
high
qualiti
complex
format
antibodi
molecul
includ
bispecif
antibodi
antibodi
fusion
protein
consist
differ
polypeptid
chain
singl
cho
cell
line
dr
hansen
discuss
applic
dilig
cell
line
select
strategi
support
high
throughput
analyt
method
critic
success
identif
cell
clone
wellcharacter
cell
properti
give
rise
stabl
product
profil
high
product
qualiti
ernest
smith
vaccinex
inc
provid
detail
antibodi
discoveri
platform
enabl
effici
mammalian
cellbas
express
librari
human
antibodi
fulllength
igg
format
surfac
vaccinia
viru
upon
infect
mammalian
cell
antibodi
incorpor
newli
produc
viru
display
surfac
host
cell
approach
combin
advantag
viru
pan
cell
sort
one
technolog
conclud
session
diana
bowley
abbvi
bioresearch
center
give
overview
informat
platform
support
design
clone
express
purif
larg
panel
bispecif
dualvari
domain
immunoglobulin
dvdigtm
candid
dr
bowley
describ
platform
also
use
assess
properti
molecul
includ
select
cross
reactiv
epitop
bind
stabil
system
thu
enabl
parallel
engin
dvdig
molecul
via
combinatori
design
vdomain
linker
posit
length
fc
chain
afternoon
track
emerg
clinic
data
therapeut
antibodi
adc
chair
loui
weiner
georgetown
univers
medic
center
therapeut
antibodi
adc
import
clinic
applic
treatment
cancer
diseas
session
focu
primarili
emerg
data
antibodi
target
immun
checkpoint
treat
cancer
start
antibodi
target
present
nil
lonberg
bristolmy
squibb
field
rapidli
expand
includ
antibodi
target
immun
checkpoint
present
omid
hamid
angel
clinic
research
institut
jonathan
cheng
merck
present
edward
cha
genentech
antibodi
addit
immun
checkpoint
develop
moreov
combin
immun
modul
antibodi
ipilimumab
plu
demonstr
extrem
promis
activ
patient
advanc
malign
melanoma
import
emerg
clinic
indic
includ
nonsmal
cell
lung
cancer
present
hossein
borghaei
fox
chase
cancer
center
final
adc
begin
fulfil
clinic
promis
exemplifi
success
adotrastuzumab
emtansin
maytansinoid
conjug
present
kyle
holen
abbvi
anoth
agent
show
earli
promis
target
activ
egfr
deliv
cytotox
payload
relat
advanc
promis
improv
cancer
therapi
antibodi
societi
special
session
round
wednesday
program
meet
particip
get
glimps
futur
antibodi
societi
special
session
antibodi
watch
commerci
pipelin
antibodi
therapeut
highli
dynam
multitud
transit
occur
year
molecul
advanc
clinic
phase
onto
market
presid
antibodi
societi
janic
reichert
reichert
biotechnolog
consult
llc
editorinchief
mab
recap
import
event
includ
first
approv
antibodi
therapeut
vedolizumab
ramucirumab
siltuximab
nivolumab
pembrolizumab
discuss
expect
recent
result
suggest
activ
may
even
greater
banner
year
transit
pivot
studi
well
first
market
approv
relev
data
transit
first
phase
studi
occur
project
summar
metric
novel
antibodi
therapeut
develop
evolv
field
biosimilar
antibodi
develop
also
discuss
track
antibodi
repertoir
next
gener
sequenc
data
analysi
storag
share
chair
jami
k
scott
simon
fraser
univers
advent
nextgener
sequenc
ng
allow
deep
analysi
immun
repertoir
term
collect
refer
antibodi
repertoir
compris
bcell
receptor
bcr
antibodi
produc
bcell
plasma
cell
respect
tcell
receptor
tcr
repertoir
product
rearrang
vl
vh
gene
encod
variabl
domain
antibodi
bcell
receptor
similarli
gene
encod
variabl
domain
tcell
receptor
b
tcell
mrna
encod
antibodi
tcr
plasmid
dna
encod
phage
librari
constitut
materi
ng
immun
repertoir
deriv
v
region
ten
million
cell
phage
clone
sequenc
bulk
high
coverag
ie
million
arriv
dna
sequenc
reflect
repertoir
sequenc
divers
rel
copi
number
data
progress
phage
librari
screen
precis
follow
antibodi
tcr
repertoir
assess
depth
eg
follow
residu
diseas
treatment
leukemia
lymphoma
differ
among
b
andor
tcell
popul
assess
healthi
vs
diseas
state
vaccin
well
somat
mutat
among
clonal
relat
antibodi
identifi
analyz
reveal
phylogenet
histori
bcell
clone
purpos
session
provid
particip
year
antibodi
engin
therapeut
confer
tast
current
progress
immunerepertoir
ng
data
acquisit
analysi
storag
share
first
half
session
focu
immun
repertoir
librari
technolog
data
analysi
brandon
dekoski
univers
texa
austin
present
new
method
highthroughput
analysi
pair
antibodybcr
heavi
light
chain
variableregion
vh
vl
sequenc
b
cell
plasma
cell
sara
angelo
lo
alamo
nation
laboratori
discuss
ng
dataanalysi
tool
group
use
identifi
select
antibodi
clone
phagedisplay
singlechain
scfv
antibodi
librari
final
rami
arnaout
beth
israel
deaco
medic
center
present
analysi
ng
data
murin
bone
marrow
splenocyt
identifi
vh
gene
nonproduct
follicular
marginalzon
bcell
subset
analysi
reveal
bias
vh
geneseg
usag
among
bcell
subset
differenti
pathway
follicular
marginalzon
b
cell
matur
second
half
session
focu
storag
share
immun
repertoir
ng
data
felix
breden
simon
fraser
univers
present
ireceptor
distribut
data
manag
system
share
compar
immun
repertoir
scheme
user
store
primari
data
local
site
bring
ireceptor
system
analysi
user
data
david
johnson
gigagen
inc
present
clonalysi
cloudbas
web
portal
storag
analysi
ng
immun
repertoir
data
develop
tool
rapidli
perform
analysi
vgene
assign
cluster
relat
sequenc
final
lindsay
cowel
ut
southwestern
medic
center
present
vdjserver
web
portal
store
analyz
share
archiv
immun
repertoir
data
also
develop
standard
data
share
interoper
analysi
pipelin
support
data
reproduc
track
best
world
antibodi
enhanc
multipl
function
chair
mark
r
alfenito
engen
bio
inc
class
drug
antibodi
uniqu
complex
come
readyarm
multipl
function
includ
target
function
repres
variabl
region
block
agon
antagon
function
effector
function
contain
within
c
domain
confer
adcc
opson
complement
function
session
cover
sever
strategi
take
advantag
enhanc
flexibl
natur
antibodi
function
zhenp
zhu
kadmon
china
discuss
sever
format
program
death
ligand
antibodi
includ
immunoconjug
show
vitro
vivo
data
efficaci
takehisa
kitazawa
chugai
pharmaceut
co
show
use
bispecif
antibodi
recreat
novel
function
bind
coagul
factor
ixa
x
treatment
hemophilia
first
time
hemophilia
treatment
report
antibodi
confer
molecular
design
molecul
discuss
along
preclin
earli
clinic
data
bent
jakobsen
immunocor
ltd
also
speak
bispecif
antibodi
immtac
immun
mobil
monoclon
cell
receptor
cancer
talk
cover
engin
immtac
evid
potent
specif
kill
tumor
cell
detail
mechan
action
addit
latest
clinic
data
advanc
immtac
present
kristian
jensen
dutali
discuss
dutamab
form
bispecif
antibodi
bind
site
fv
region
engin
physic
properti
molecul
discuss
present
illustr
benefit
use
case
studi
novel
bispecif
angiogenesi
blocker
bestinclass
properti
area
affin
potenc
stabil
solubl
manufactur
toler
ronit
mazor
nation
cancer
institut
speak
engin
antibodytoxin
conjug
minim
patient
toxic
immunogen
silenc
human
cell
epitop
contain
within
molecul
dr
mazor
present
data
redesign
immunotoxin
cell
epitop
mutat
demonstr
high
cytotox
cell
isol
cancer
patient
produc
complet
remiss
mice
human
cancer
xenograft
final
david
miao
concorti
biosystem
discuss
enhanc
antibodi
efficaci
deliveri
toxic
payload
via
adc
technolog
antibodi
therapeut
noncanc
indic
chair
trudi
veldman
abbvi
last
session
meet
highlight
divers
approach
diseas
modif
antibodi
therapi
addit
block
inflammatori
diseas
promot
process
driven
proinflammatori
cytokin
focu
extend
block
neg
regul
myostatin
achiev
muscl
growth
remyelin
respect
clinic
experi
emerg
sever
antibodi
studi
inform
us
whether
preclin
promis
approach
translat
clinic
set
toni
de
fougerol
ablynx
present
uniqu
scientif
opportun
use
singl
domain
antibodi
nanobodi
experi
preclin
clinic
develop
sever
case
studi
field
inflamm
host
defens
next
dimit
dimitrov
nation
cancer
institut
discuss
signific
effort
develop
mab
sever
emerg
biodefenserel
virus
candid
therapeut
prophylact
three
except
potent
new
mab
merscov
potenti
therapi
human
describ
lioudmila
tchistiakova
pfizer
present
interest
result
studi
antibodi
myostatin
neg
regul
muscl
growth
evalu
clinic
trial
detail
studi
structur
interact
antibodi
target
may
provid
insight
superior
clinic
efficaci
obtain
antibodi
dupilumab
anti
antibodi
inhibit
signal
block
inflamm
patient
moderatetosever
atop
dermat
eosinophil
asthma
neil
graham
regeneron
pharmaceut
present
data
clinic
efficaci
safeti
dupilumab
two
condit
john
latham
alder
biopharmaceut
discuss
novel
strategi
prevent
migrain
use
potent
anticgrp
antagonist
antibodi
human
highaffin
mab
target
neuropeptid
cgrp
shown
play
import
role
migrain
initi
propag
summari
properti
antibodi
preclin
studi
efficaci
human
clinic
trial
present
multipl
sclerosi
ms
research
look
beyond
antiinflammatori
drug
halt
diseas
progress
interest
explor
neuron
repair
mechan
potenti
groundbreak
therapi
treatment
ms
neurodegen
diseas
special
interest
ongo
studi
antagonist
antibodi
neg
regul
oligodendrocyt
differenti
myelin
werner
meier
biogen
idec
discuss
discoveri
engin
develop
treatment
ms
